Prevention of osteoporosis in glucocorticoid-treated neurology patients

Clinical Neurology and Neurosurgery

Volumn 108, Issue 2, 2006, Pages 157-162

  Lozsadi, D A ^a   Peters, G ^a   Sadik, H Y ^a   Kellett, M W ^b   Fox, S H ^c   Smith, D F ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Audit; Biphosphonate; Neurology disorders; Osteoporosis; Prednisolone; Prevention

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCICHEW; CALCIUM; ETIDRONIC ACID; GLUCOCORTICOID; PREDNISOLONE; RECOMBINANT HORMONE; VITAMIN D;

ADULT; AGED; ARTICLE; BEHCET DISEASE; BONE DENSITOMETRY; CAUDA EQUINA SYNDROME; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; COGAN SYNDROME; CONTROLLED STUDY; DERMATOMYOSITIS; ENCEPHALITIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; LYMPHOMA; MALE; MONONEUROPATHY MULTIPLEX; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELITIS; MYOCLONUS; NEUROLOGIC DISEASE; OPTIC NEURITIS; OSTEOPOROSIS; POLYNEUROPATHY; PRACTICE GUIDELINE; RISK FACTOR; SARCOIDOSIS; UNITED KINGDOM; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOCORTICOIDS; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OSTEOPOROSIS; PRACTICE GUIDELINES;

EID: 30444461209     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2005.05.008     Document Type: Article

References (26)

1. J.E. South-Paul Osteoporosis. Part I. Evaluation and assessment Am Fam Physician 63 2001 897 904
2. R. Seagger, J. Howell, H. David, and S. Gregg-Smith Prevention of secondary osteoporotic fractures - why are we ignoring the evidence? Injury 35 2004 986 988
3. M. Harris, T.V. Nguyen, G.M. Howard, P.J. Kelly, and J.A. Eisman Genetic and environmental correlations between bone formation and bone mineral density: a twin study Bone 22 1998 141 145
4. N.P. Robertson, J. Deans, and D.A. Compston Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England J Neurol Neurosurg Psychiatry 65 1998 492 496
5. J.A. Riancho Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with biphosphonate alendronate Rev Clin Esp 199 1999 349 355
6. K. Lippuner Medical treatment of vertebral osteoporosis Eur Spine J 12 2003 S132 S141
7. National guidelines for the prevention and management of corticosteroid induced osteoporosis. Bath: UK osteoporosis consensus group; 1998.
8. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP; 2002.
9. S.J. Lewis, and P.E. Smith Osteoporosis prevention in myasthenia gravis: a reminder Acta Neurol Scand 103 2001 320 322
10. K.G. Saag, R. Emkey, T.J. Schnitzer, and J.P. Brown Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 1998 292 299
11. G.M. Hall, M. Daniels, D.V. Doyle, and T.D. Spector Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids Arthritis Rheum 37 1994 1499 1505
12. G.M. Coombes, B.E. Bax, R. Eastell, and NF.A. Peel Treatment of corticosteroid-induced osteoporosis using tibolone - a randomised, double-blind, placebo-controlled trial J Bone Miner Res 15 Suppl. 2000 311
13. R.N. de Nijs, J.W. Jacobs, A. Algra, W.F. Lems, and J.W. Bijlsma Prevention and treatment of glucocorticoid-induced osteoporosis with active Vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies Osteoporos Int 15 2004 589 602
14. M.A. Valero, C. Loinaz, L. Larrodera, M. Leon, E. Moreno, and F. Hawkins Calcitonin and bisphosphonates treatment in bone loss after liver transplantation Calcif Tissue Int 57 1995 15 19
15. J. Homik, A. Cranney, B. Shea, P. Tugwell, G. Wells, and R. Adachi Biphosphonates for steroid induced osteoporosis Cochrane Database Syst Rev 2 2000 CD001347
16. D.M. Reid, R.A. Hughes, Laan RFJM, and N.A. Sacco-Gibson Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial J Bone Miner Res 15 2000 1006 1113
17. B. Frediani, P. Falsetti, F. Baldi, C. Acciai, G. Filippou, and R. Marcolongo Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound Bone 33 2003 575 581
18. P. Pitt, F. Li, P. Todd, D. Webber, S. Pack, and C. Moniz A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment Thorax 53 1998 351 356
19. S.J. Gallacher, J.A. Fenner, K. Anderson, F.M. Bryden, S.W. Banham, and F.C. Logue Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study Thorax 47 1992 932 936
20. J.G. Brecht, H.P. Kruse, W. Mohrke, A. Oestreich, and E. Huppertz Health-economic comparison of three recommended drugs for the treatment of osteoporosis Int J Clin Pharmacol Res 24 2004 1 10
21. M.E. Lloyd, T.D. Spector, and R. Howard Osteoporosis in neurological disorders J Neurol Neurosurg Psychiatry 68 2000 543 547
22. M.D. Smith, S.P. Cheah, K. Taylor, and M.J. Ahern Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital J Rheumatol 28 2001 566 570
23. D.M. Hougardy, G.M. Peterson, M.D. Bleasel, and C.T. Randall Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25 2000 227 234
24. B. Ettinger, P. Chidambaran, and A. Pressman Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs Am J Manag Care 7 2001 597 605
25. E. Soucy, N. Bellamy, J.D. Adachi, J.E. Pope, J. Flynn, and E. Sutton A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists J Rheumatol 27 2000 1506 1512
26. G.D. Smith, D.L. Stevens, and G.N. Fuller Myasthenia gravis, corticosteroids and osteoporosis prophylaxis J Neurol 248 2001 151